1. Anderson, D., Bishop, J. B., Garner, R. C., Ostrosky-Wegman, P., and Selby, P. B. (1995). Cyclophosphamide: Review of its mutagenicity for an assessment of potential germ cell risks. Mutat. Res.330,115–181.
2. Baumann, F., Lorenz, C., Jaehde, U., and Preiss, R. (1999). Determination of cyclophosphamide and its metabolites in human plasma by high-performance liquid chromatography-mass spectrometry. J. Chromatogr B Biomed. Sci. Appl.729,297–305.
3. Cai, Y., Wu, M. H., Xu-Welliver, M., Pegg, A. E., Ludeman, S. M., and Dolan, M. E. (2000). Effect of O6-benzylguanine on alkylating agent-induced toxicity and mutagenicity. In Chinese hamster ovary cells expressing wild-type and mutant O6-alkylguanine-DNA alkyltransferases. Cancer Res.60,5464–5469.
4. Christiansen, C., Christensen, M. S., McNair, P., Hagen, C., Stocklund, K. E., and Transbol, I. (1980). Prevention of early postmenopausal bone loss: Controlled 2-year study in 315 normal females. Eur. J. Clin. Invest.10,273–279.
5. Colvin, M., Brundrett, R. B., Kan, M. N., Jardine, I., and Fenselau, C. (1976). Alkylating properties of phosphoramide mustard. Cancer Res.36,1121–1126.